Vnitr Lek 2021, 67(1):e22-e25 | DOI: 10.36290/vnl.2021.013

Pitfalls of solving polypharmacy problems

Štefan Alušík1, Zoltán Paluch2
1 Katedra vnitřního lékařství IPVZ, Praha
2 Ústav farmakologie 2. LF UK, Praha

Polymedication is associated with a higher incidence of negative health indicators including falls, morbidity and mortality. Despite efforts, the solution to this problem is still unsatisfactory. The two main causes of polymedication are population aging and polymorbidity and, on the other hand, the development of the pharmaceutical industry and the availability of a wide range of medicines. The authors discuss the main shortcomings in the investigation of this issue, such as inconsistent terminology used, methodological shortcomings in data acquisition, lack of recommended guidelines for the polymorbid patients treatment, etc. They discuss whether polymedication is the cause or marker of increased falls, frailty and mortality. In the end they critically evaluate possible solution of polymedication in future - personalised medicine.

Keywords: polypharmacy, polymorbidity, guidelines, personalised medicine.

Published: March 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Alušík Š, Paluch Z. Pitfalls of solving polypharmacy problems. Vnitr Lek. 2021;67(1):e22-25. doi: 10.36290/vnl.2021.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Eurostat Statistics Explained.File: Population age structure by major age groups, 2008 and 2018 (% of the total population).png. Dostupné z WWW: https://ec.europa.eu/eurostat/statisticsexplained/index.php?title=File:Population_age_structure_by_major_age_groups,_2008_and_2018_(%25_of_the_total_population).png
    2. Mair A, Wilson M, Dreischulte T. Addressing the Challenge of Polypharmacy. Annu Rev Pharmacol Toxicol. 2020; 60: 661-681. Dostupné z DOI:https://doi.org/10.1146/annurev‑pharmtox-010919-023508 Go to original source...
    3. Newnham W. Remarks on the Present Aspect of Medicine. Provincial Medical and Surgical Journal 1848; 12(11): 281-285. Dostupné z www: https://www.jstor.org/stable/25500348?seq=1#metadata_info_tab_contents Go to original source... Go to PubMed...
    4. Masnoon N, Shakib S, Kalisch‑Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1): 230. Dostupné z DOI: https://doi.org/10.1186/s12877-017-0621-2 Go to original source... Go to PubMed...
    5. Lee EA, Brettler JW, Kanter MH et al. Refining the Definition of Polypharmacy and Its Link to Disability in Older Adults: Conceptualizing Necessary Polypharmacy, Unnecessary Polypharmacy, and Polypharmacy of Unclear Benefit. Perm J. 2020; 24: 18.212. Dostupné z DOI: https://doi.org/10.7812/TPP/18.212 Go to original source... Go to PubMed...
    6. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and sound.The King's Fund, London 2013,56 s. Dostupné z WWW: https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/polypharmacy‑and‑medicines‑optimisation‑kingsfund‑nov13.pdf
    7. Medication Safety in Polypharmacy. Geneva: World Health Organization; 2019 (WHO/UHC/SDS/2019.11). Licence: CC BY‑NC‑SA 3.0 IG. Dostupné z WWW:https://apps.who.int/iris/bitstream/handle/10665/325454/WHO‑UHC‑SDS-2019.11-eng.pdf?ua=1
    8. Bursztyn M. Hypertension, Its Treatment, Frailty, Falls, and Mortality. Hypertension. 2017; 70(2): 253-254. Dostupné z DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.09689. Go to original source... Go to PubMed...
    9. Sabaté E, et al. Adherence to Long‑Term Therapies: Evidence for Action. WHO, Geneva, 2003,199 p. Dostupné z WWW: https://www.who.int/chp/knowledge/publications/adherence_report/en/
    10. Thrall G, Lip G, Lane D. Compliance with pharmacological therapy in hypertension: can we do better, and how?. J Hum Hypertens 2004; 18: 595-597. https://doi.org/10.1038/sj.jhh.1001722. Go to original source... Go to PubMed...
    11. Midão L, Giardini A, Menditto E, Kardas P, Costa E. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. Arch Gerontol Geriatr. 2018;78:213-220. Dostupné z DOI: https://doi.org/10.1016/j.archger.2018. 06. 018. Go to original source...
    12. Wastesson JW, Canudas‑Romo V, Lindahl‑Jacobsen R, Johnell K. Remaining Life Expectancy With and Without Polypharmacy: A Register‑Based Study of Swedes Aged 65 Years and Older. J Am Med Dir Assoc. 2016; 17(1): 31-35.Dostupné z DOI: https://doi.org/10.1016/j.jamda.2015. 07. 015. Go to original source... Go to PubMed...
    13. Kojima T. The Need for Actions Against Polypharmacy in Older People With Frailty. Ann Geriatr Med Res. 2018;22(3):111-116. Dostupné z DOI: https://doi.org/10.4235/agmr.2018. 22. 3.111. Go to original source...
    14. Saum KU, Schöttker B, Meid AD, Holleczek B, Haefeli WE, Hauer K et al. Is Polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J Am Geriatr Soc 2017; 65: e27-32. Dostupné z DOI: https://doi.org/10.1111/jgs.1471. Go to original source... Go to PubMed...
    15. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta‑analysis. J Am Pharm Assoc (2003). 2017; 57(6): 729-738.e10. Dostupné z DOI: https://doi.org/10.1016/j.japh.2017. 06. 002. Go to original source... Go to PubMed...
    16. Mair A, Fernandez‑Llimos F, Alonso A et al. Polypharmacy Management by 2030:a patient safety challenge,2nd edition.The Simpathy Consorcium 2017; 56p. Dostupné z WWW:http://www.simpathy.eu/sites/default/files/Managing_polypharmacy2030-web.pdf.
    17. Mangin D, Bahat G, Golomb BA et al. International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action. Drugs Aging. 2018; 35(7): 575-587. Dostupné z DOI: https://doi.org/10.1007/s40266-018-0554-2. Go to original source... Go to PubMed...
    18. Johnell K. The controversies surrounding polypharmacy in old age‑where are we? Expert Rev Clin Pharmacol. 2018; 11(9): 825-827. Dostupné z DOI: https://doi.org/10.1080/17512433.2018.1510313. Go to original source... Go to PubMed...
    19. Huizer‑Pajkos A, Kane AE, Howlett SE et al. Adverse Geriatric Outcomes Secondary to Polypharmacy in a Mouse Model: The Influence of Aging. J Gerontol A Biol Sci Med Sci. 2016; 71(5): 571-577. Dostupné z DOI: https://doi.org/10.1093/gerona/glv046. Go to original source... Go to PubMed...
    20. Iriart JAB. Precision medicine/personalized medicine: a critical analysis of movements in the transformation of biomedicine in the early 21st century. Cad. Saúde Pública 2019; 35(3): e00153118. Dostupné z DOI:https://doi.org/10.1590/0102-311x00153118. Go to original source... Go to PubMed...
    21. Nimmesgern E, Benediktsson I, Norstedt I. Personalized Medicine in Europe. Clin Transl Sci 2017; 10(2): 61-63. Dostupné z DOI: https://doi.org/10.1111/cts.12446. Go to original source... Go to PubMed...
    22. Molokhia M, Majeed A. Current and future perspectives on the management of polypharmacy. BMC Fam Pract. 2017; 18: 70.Dostupné z DOI: http://doi.org/10.1186/s12875-017-0642-0https://www.ncbi.nlm.nih.gov/pubmed/28587644. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.